Nektar Therapeutics Announces Third Quarter 2026 Financial Results
NEKTAR THERAPEUTICS (NKTR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nektar Therapeutics Announces Third Quarter 2026 Financial Results SAN FRANCISCO, November 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced its financial results for the third quarter ended September 30, 2026, and provided a business update
How this was made
The 30-second read
Why it matters
The earnings release introduces higher operating losses and R&D spend, offset by a sizable cash balance, creating a mixed short‑term outlook.
Market read
Primary biotech earnings release with new financial metrics and trial updates; relevant for short‑term traders and longer‑term investors in immunology therapeutics.
What to watch
Phase 3 trial initiations and upcoming topline data in 2028 could provide upside catalysts beyond the earnings disappointment.
Nektar reports Q3 2026 revenue of $9.4 million and a net loss of $55.7 million as Phase 3 rezpegaldesleukin spending rises
Revenue fell year over year in both the quarter and the nine months, and operating costs rose sharply in Q3 (R&D up to $44.1 million from $27.3 million). Net loss widened to $55.7 million from $35.5 million. Cash and investments rose to $952.9 million from $245.8 million at December 31, 2025, and the company reports that all three ZENITH AD registrational trials have been initiated, which supports the pipeline read.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenue, Q3 2026GAAP | $9.4M | – | – |
| Total revenue, nine months 2026GAAP | $30.4M | – | – |
| Non-cash royalty revenue related to the sales of future royalties, Q3 2026GAAP | $9.39M | – | – |
| Non-cash royalty revenue related to the sales of future royalties, nine months 2026GAAP | $30.38M | – | – |
| License, collaboration and other revenue, Q3 2026GAAP | - | – | – |
| License, collaboration and other revenue, nine months 2026GAAP | - | – | – |
| Total operating costs and expenses, Q3 2026GAAP | $67.2M | – | – |
| Total operating costs and expenses, nine months 2026GAAP | $169.6M | – | – |
| Research and development expense, Q3 2026GAAP | $44.1M | – | – |
| Research and development expense, nine months 2026GAAP | $118.9M | – | – |
| General and administrative expense, Q3 2026GAAP | $24.6M | – | – |
| General and administrative expense, nine months 2026GAAP | $50.8M | – | – |
| Restructuring and impairment, Q3 2026GAAP | −$1.50M | – | – |
| Restructuring and impairment, nine months 2026GAAP | −$130K | – | – |
| Loss from operations, Q3 2026GAAP | −$57.80M | – | – |
| Loss from operations, nine months 2026GAAP | −$139.2M | – | – |
| Non-cash interest expense on liabilities related to the sales of future royalties, Q3 2026GAAP | −$6.76M | – | – |
| Non-cash interest expense on liabilities related to the sales of future royalties, nine months 2026GAAP | −$21.91M | – | – |
| Interest income, Q3 2026GAAP | $9.58M | – | – |
| Interest income, nine months 2026GAAP | $23.17M | – | – |
| Total non-operating income (expense), net, Q3 2026GAAP | $2.76M | – | – |
| Total non-operating income (expense), net, nine months 2026GAAP | $760K | – | – |
| Loss from equity method investment, Q3 2026GAAP | −$583K | – | – |
| Loss from equity method investment, nine months 2026GAAP | −$2.65M | – | – |
| Net loss, Q3 2026GAAP | −$55.65M | – | – |
| Net loss, nine months 2026GAAP | −$141.2M | – | – |
| Basic and diluted net loss per share, Q3 2026GAAP | $(1.63) per share | – | – |
| Basic and diluted net loss per share, nine months 2026GAAP | $(4.60) per share | – | – |
| Cash and investments in marketable securities at September 30, 2026GAAP | $952.9M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Non-cash royalty revenue related to the sales of future royaltiesThe filing does not explain the change in this revenue line. Prior-year figures are $11,490 thousand (Q3 2025) and $33,125 thousand (nine months 2025). | $9,386 thousand (Q3 2026); $30,378 thousand (nine months 2026) | – | – |
| License, collaboration and other revenueNo amount is printed for 2026. Prior-year amounts were $300 thousand for Q3 2025 and for the nine months of 2025. The filing gives no explanation. | - (Q3 2026 and nine months 2026, as printed) | – | – |
Capital returns
- No share repurchases or dividends are reported in the filing.
- Weighted average shares outstanding used in computing basic and diluted net loss per share were 34,178,219 for Q3 2026 versus 18,946,559 for Q3 2025, and 30,690,968 for the nine months of 2026 versus 15,716,396 for the nine months of 2025. The filing does not describe the source of these share changes.
What drove it
- Company explanation for R&D increase: R&D expense increased primarily due to activities to support the Phase 3 ZENITH AD program in atopic dermatitis and the Phase 3 ZENITH AA program in alopecia areata, as well as manufacturing activities associated with rezpegaldesleukin.
- Company explanation for G&A movement: G&A expense increased for the third quarter of 2026 primarily due to an increase in legal expenses in that quarter, and decreased for the first nine months of 2026 primarily due to a decrease in legal expenses in that period.
- Restructuring and impairment was a benefit of $(1,504) thousand in Q3 2026 versus a charge of $140 thousand in Q3 2025. The filing does not state the reason.
- Interest income rose to $9,578 thousand in Q3 2026 from $2,819 thousand in Q3 2025. The filing does not state the reason for the change.
- Non-cash royalty revenue fell to $9,386 thousand in Q3 2026 from $11,490 thousand in Q3 2025. The filing does not state the reason for the change.
Concerns
- Total revenue declined to $9.4 million from $11.8 million in Q3 and to $30.4 million from $33.4 million for the nine months.
- Total operating costs and expenses rose to $67.2 million from $43.5 million in Q3, and loss from operations widened to $(57,802) thousand from $(31,672) thousand.
- Net loss widened to $55.7 million from $35.5 million in Q3, even though basic and diluted net loss per share improved to $(1.63) from $(1.87). The filing shows weighted average shares rising to 34,178,219 from 18,946,559.
- Non-cash interest expense on royalty-related liabilities was $(6,763) thousand in Q3 2026 versus $(6,047) thousand in Q3 2025, and $(21,911) thousand for the nine months versus $(16,415) thousand.
- The company reports the G&A increase in Q3 was driven by higher legal expenses, which the filing does not quantify beyond the line items shown.
What to watch
- ZENITH AA registrational trial in alopecia areata, which the CEO said is on track to begin in December 2026, earlier than previously planned.
- Initial topline data from the ZENITH AD program, expected in mid-2028, and the BLA submission targeted for 2029.
- Evaluation of less frequent rezpegaldesleukin dosing (Q4W or Q12W) beyond the 52-week induction period in alopecia areata, as described in the release.
- Trend in R&D expense, which rose to $118.9 million for the nine months of 2026 from $87.6 million, given the Phase 3 programs.
- Trend in legal expenses within G&A, which the company identifies as a driver of the Q3 increase.
- The filing contains no financial guidance for revenue, operating expenses or tax rate.
Balance sheet and cash flow
- Cash and investments in marketable securities were $952.9 million at September 30, 2026, compared with $245.8 million at December 31, 2025, as stated by the company.
- Balance sheet at September 30, 2026 versus December 31, 2025 (in thousands): cash and cash equivalents 34,686 versus 15,116; short-term investments 579,671 versus 230,636; long-term investments 338,500 versus none printed; total assets 1,037,251 versus 280,406.
- Total liabilities were 187,529 versus 190,574. Liabilities related to the sales of future royalties, net, were 54,787 versus 63,157. Operating lease liabilities, less current portion, were 50,998 versus 65,256.
- Total stockholders' equity was 849,722 versus 89,832. Accumulated deficit was (3,901,463) versus (3,760,286). Capital in excess of par value was 4,755,130 versus 3,850,099.
- No operating cash flow, investing cash flow, financing cash flow or free cash flow figures are printed in the filing.
Analysis
Nektar reported third quarter 2026 total revenue of $9.4 million, against $11.8 million a year earlier, and nine-month revenue of $30.4 million against $33.4 million. Both lines are non-cash royalty revenue related to the sales of future royalties, and the license line printed no 2026 amount. The filing does not give a reason for the decline in royalty revenue, so the decline should be read as a fact set beside the prior year rather than as an explained trend.
Costs moved sharply higher. Total operating costs and expenses were $67.2 million in Q3 2026 against $43.5 million, and R&D expense was $44.1 million against $27.3 million. The company attributes the R&D increase primarily to activities supporting the Phase 3 ZENITH AD and ZENITH AA programs and to manufacturing activities for rezpegaldesleukin. G&A expense was $24.6 million against $16.1 million in the quarter, which the company attributes to higher legal expenses. For the nine months, G&A was lower at $50.8 million against $57.5 million, with the company citing a decrease in legal expenses for that period. Restructuring and impairment was a benefit of $(1,504) thousand in Q3 2026.
Below the operating line, interest income increased to $9,578 thousand from $2,819 thousand in Q3, and non-operating income net was $2,756 thousand against an expense of $(3,349) thousand. Non-cash interest expense on royalty-related liabilities was $(6,763) thousand. These items partly offset the operating loss, but the net loss still widened to $(55,651) thousand from $(35,522) thousand in Q3, and to $(141,177) thousand from $(127,997) thousand for the nine months. Basic and diluted net loss per share improved to $(1.63) from $(1.87) in Q3 and to $(4.60) from $(8.14) for the nine months. The weighted average share count rose to 34,178,219 from 18,946,559 in Q3, so the per-share figure and the net loss move in different directions and the reader should weigh both.
The balance sheet is much larger than a year earlier. Cash and investments in marketable securities were $952.9 million at September 30, 2026, against $245.8 million at December 31, 2025, and total stockholders' equity rose to 849,722 thousand from 89,832 thousand. The filing does not describe the financing or other transactions behind these changes, and it prints no operating or free cash flow figures for the period. The company reports no share repurchases or dividends.
Operationally, the release centres on the rezpegaldesleukin program. The company says all three ZENITH AD registrational trials in atopic dermatitis have been initiated, with ZENITH AD-3 started in October 2026, and that the ZENITH AA trial in alopecia areata is on track to begin in December. Topline ZENITH AD data are expected in mid-2028 and a BLA is targeted for 2029. The release gives no financial guidance, so there is no printed outlook against which to test the quarter.
Management, verbatim
This was a pivotal quarter for Nektar as we moved rezpegaldesleukin quickly into Phase 3 development
Howard Robin, President and Chief Executive Officer of Nektar
Not in the filing
stated, not guessed- No financial guidance for revenue, gross margin, operating expenses or tax rate is provided in the filing.
- Prior-year percentage changes for revenue, operating expenses, net loss and per-share figures are not printed and were not calculated.
- Prior-quarter (Q2 2026) figures are not in the filing.
- Operating, investing and financing cash flow figures and free cash flow are not printed.
- Cash and investments at December 31, 2025 are printed in the text but are not a prior-year figure for the same period, so the prior_year field is null.
- Reasons for the decline in non-cash royalty revenue, the increase in interest income and the restructuring and impairment benefit are not stated.
- Sources of the increase in weighted average shares outstanding are not described.
- No gross margin is reported because the company has no cost of sales line.
- No share price reaction, consensus estimates or analyst expectations are included in the filing.
- The previous outlook covered milestones through 2028 and 2029 with no numeric guidance for a quarter, so there is nothing to compare for Q3 2026.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Nektar Therapeutics (NASDAQ: NKTR) filed an 8‑K reporting its Q3 2026 financial results and updates on its rezpegaldesleukin Phase 3 programs for atopic dermatitis and alopecia areata.
Ticker impact
Q3 2026 results show higher net loss and operating expenses despite cash increase, indicating short‑term pressure on the stock.
downward pressure as investors digest larger loss and higher R&D spend
The report reveals a $55.7M net loss versus $35.5M a year ago and a 53% rise in R&D expense, which typically depresses biotech stocks in the near term.
Market effects
Highlights continued cash burn in late‑stage biotech, may affect peer valuations in the immunology space.
US biotech sector may see modest pullback in pre‑market trading.
Limited to investors tracking US‑listed biotech pipelines.
Counterpoint
Strong cash position ($952.9M) could support future milestones and may attract long‑term investors despite short‑term loss.
Key entities
- ExecutiveHoward Robin
President and CEO of Nektar, provided commentary on the Phase 3 program progress.


